002210 — Dongsung Pharmaceutical Co Share Price
Last trade - 00:00- KR₩102bn
- KR₩152bn
- KR₩89bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.71 | ||
| Price to Tang. Book | 2.78 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.16 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.19% | ||
| Return on Equity | -8.19% | ||
| Operating Margin | -3.62% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 86,536.76 | 87,799.93 | 84,407.66 | 93,328.19 | 88,593.59 | n/a | n/a | -0.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dongsung Pharmaceutical Co., Ltd. is a Korea-based company engaged in the manufacture of pharmaceuticals. The Company’s products include anti-rheumatic, anti-inflammatory analgesics, anti-inflammatory enzymes, drugs for cardiovascular system, gastrointestinal drugs, antispasmodic agents, respiratory agents, anti-histamine, dermatologicals, antibiotics, antidiarrheals, antifungals, oral hypoglycemic agents, hormones, hypnotics and others. It also produces hair dyes and cosmetics. The Company distributes its products within domestic market and to overseas markets.
Directors
- Yang Gu Lee CEO (51)
- Yeon Su Kim VMG (72)
- Jung Mu Gwon VPR (66)
- Yin Gyu Kim MDR (58)
- Sang Yi Nam OTH (53)
- Tae Ri Gwon OTH (65)
- Jeong Man Yim NID (67)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- November 25th, 1957
- Public Since
- January 19th, 1990
- No. of Shareholders
- 23,893
- No. of Employees
- 337
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 22,865,988
- Address
- Dongsung Bldg., SEOUL, 01340
- Web
- http://dongsung-pharm.com
- Phone
- +82 269113600
- Auditors
- Ernst & Young Han Young
Upcoming Events for 002210
Similar to 002210
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
As of Today at 14:20 UTC, shares in Dongsung Pharmaceutical Co are trading at KR₩4,480. This share price information is delayed by 15 minutes.
Shares in Dongsung Pharmaceutical Co last closed at KR₩4,480 and the price had moved by -21.33% over the past 365 days. In terms of relative price strength the Dongsung Pharmaceutical Co share price has underperformed the FTSE Developed Asia Pacific Index by -34.26% over the past year.
There is no consensus recommendation for this security.
Find out moreDongsung Pharmaceutical Co does not currently pay a dividend.
Dongsung Pharmaceutical Co does not currently pay a dividend.
Dongsung Pharmaceutical Co does not currently pay a dividend.
To buy shares in Dongsung Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩4,480, shares in Dongsung Pharmaceutical Co had a market capitalisation of KR₩102bn.
Here are the trading details for Dongsung Pharmaceutical Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 002210
Based on an overall assessment of its quality, value and momentum Dongsung Pharmaceutical Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dongsung Pharmaceutical Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -23.44%.
As of the last closing price of KR₩4,480, shares in Dongsung Pharmaceutical Co were trading -13.01% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Dongsung Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩4,480.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Dongsung Pharmaceutical Co's management team is headed by:
- Yang Gu Lee - CEO
- Yeon Su Kim - VMG
- Jung Mu Gwon - VPR
- Yin Gyu Kim - MDR
- Sang Yi Nam - OTH
- Tae Ri Gwon - OTH
- Jeong Man Yim - NID